CHMP recommends EU approval of Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer

    NEXT STORY
    Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
    PREV STORY
    Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease

    author_avatar
    NASDAQ Market News

    Global Infusion Pumps Industry

    author_avatar
    NASDAQ Market News

    Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director

    author_avatar
    NASDAQ Market News